Aug 21, 2023: New Arthroplasty Register profile added

The Swedish Arthroplasty Register (SAR) is a National Quality Register. It is a merger of the two oldest national arthroplasty registers, the Swedish Knee Arthroplasty Register and the Swedish Hip Arthroplasty Register, including knee replacements since 1975, hip replacements since 1979, hemiarthroplasties since 2005, and knee osteotomies since 2013. Reoperations, revisions and other procedures, related to the knee or hip are registered, as well as patient-reported outcome(s).

Swedish Arthoplasty Register (Sweden)

Database Contact Data

Professor Ola Rolfson
The Swedish Arthroplasty Register
413 45 Gothenburg 
SWEDEN
Email: ola.rolfson@vgregion.se

Alternate Contact

The Swedish Arthroplasty Register
413 45 Gothenburg 
SWEDEN
Phone: +46 10 441 29 31
Email: slr@registercentrum.se

References of Studies Using/Describing Database

1. Jolbäck P, Bedeschi Rego De Mattos C, Rogmark C, Chen AF, Nauclér E, Tsikandylakis G. Patient-reported Outcomes After Primary Total Hip Arthroplasty Are Not Affected by the Sex of the Surgeon: A Register-based Study of 8,383 Procedures in Western Sweden. J Am Acad Orthop Surg. 2023 Jul 1;31(13):692-700. 

2. Dale H, Fenstad AM, Hallan G, Overgaard S, Pedersen AB, Hailer NP, Kärrholm J, Rolfson O, Eskelinen A, Mäkelä KT, Furnes O. Increasing risk of revision due to infection after primary total hip arthroplasty: results from the Nordic Arthroplasty Register Association. Acta Orthop. 2023 Jun 27;94:307-315. 

3. Gustafsson K, Kvist J, Eriksson M, Rolfson O. What Factors Identified in Initial Osteoarthritis Management Are Associated With Poor Patient-reported Outcomes After THA? A Register-based Study. Clin Orthop Relat Res. 2023 May 9;481(9):1732–42.

4. Itayem R, Rolfson O, Mohaddes M, Kärrholm J. What is the Role of Stem Size and Offset in the Risk of Nonseptic Revision of the Exeter® 150-mm Stem? A Study From the Swedish Arthroplasty Register. Clin Orthop Relat Res. 2023 Apr 28;481(9):1689–99.

5. Ighani Arani P, Wretenberg P, Stenberg E, Ottosson J, W-Dahl A. Total knee arthroplasty and bariatric surgery: change in BMI and risk of revision depending on sequence of surgery. BMC Surg. 2023 Mar 10;23(1):53.

6. Lagergren J, Mukka S, Wolf O, Nauclér E, Möller M, Rogmark C. Conversion to Arthroplasty After Internal Fixation of Nondisplaced Femoral Neck Fractures: Results from a Swedish Register Cohort of 5,428 Individuals 60 Years of Age or Older. J Bone Joint Surg Am. 2023 Mar 1;105(5):389-396.

7. Cöster MC, Bremander A, Nilsdotter A. Patient-reported outcome for 17,648 patients in 5 different Swedish orthopaedic quality registers before and 1 year after surgery: an observational study. Acta Orthop. 2023 Jan 23;94:1-7.

8. Jolbäck P, Mukka S, Wetterling K, Mohaddes M, Garland A. Patient-surgeon sex discordance impacts adverse events but does not affect patient-reported satisfaction after primary total hip arthroplasty: a regional register-based cohort study. Acta Orthop. 2022 Dec 27;93:922–9.

9. Thompson O, W-Dahl A, Stefánsdóttir A. Increased short- and long-term mortality amongst patients with early periprosthetic knee joint infection. BMC Musculoskelet Disord. 2022 Dec 6;23(1):1069. 

10. Rönnquist SS, Lagergren J, Viberg B, Möller M, Rogmark C. Rate of conversion to secondary arthroplasty after femoral neck fractures in 796 younger patients treated with internal fixation: a Swedish national register-based study. Acta Orthop. 2022 Jun 14;93:547-553.

Aug 16, 2023: New US DB profile with ~300 Million records added!

Started in 2014, STATinMED’s licensed all-payer medical, and pharmacy claims dataset (STATinMED Real World Data Insights) provides insight into approximately 80% of the US healthcare system. These data are comparable with other all-payer claims repositories as they are sourced directly from claims clearinghouses, which are responsible to manage claims transactions between payers and providers, offering comprehensive coverage at the patient level across the US healthcare system.

STATinMED Real World Data Insights (USA)

Database Contact Data

Keshia Maughn
SVP/Principal, RWE (STATinMED RWD Insights)
STATinMED, LLC
13101 Preston Rd Suite 110, #3395
Dallas, TX 75240
USA
Phone:+1 214-480-4946
Email: kmaughn@statinmed.com

Alternate Contact

N/A

References of Studies Using/Describing Database

1. Shoaib S, Feliciano J, Dasenbrook EC, Maynard J, Batchu L, Mohanty M, Lauterio M, Feld AJ. Real-world disease burden, mortality, and healthcare resource utilization associated with bronchiectasis. Chron Respir Dis. 2025 Jan-Dec;22:14799731241310897.

2. Vo R, Barhoush Y, Batchu L, Adams S, Setzen G. All-cause claims analysis of the LATERA absorbable nasal implant vs surgical repair in patients with nasal valve collapse. J Med Econ. 2024 Jan-Dec;27(1):1099-1107.

3. Seigel L, Shoaib S, Maughn K, Foster M, Shah S, Batchu L, Wittstock K, Alexis A. Health disparities in psoriasis: geographic barriers to access in the United States. J Dermatolog Treat. 2024 Dec;35(1):2365820.

4. Zhao R, Ding Z, Gupta P, Gozalo L, Bruette R, Johnson VM, Maughn K, Liu Y, Kachroo S. Evaluation of Treatment Patterns and Maintenance Dose Titration Among Patients With Crohn's Disease Initiating Biologics With 3 Years of Follow-Up. J Health Econ Outcomes Res. 2023 Nov 20;10(2):111-120.

5. Navari RM, Nelson WW, Shoaib S, Singh R, Zhang W, Bailey WL. Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy. Adv Ther. 2023 Jul;40(7):3217-3226.

6. Escobar M, Bullano M, Mokdad AG, Caicedo J, Schultz BG, Fan Q, Verma S. A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors. Expert Rev Hematol. 2023 Jun;16(6):467-474.

7. Terrault N, Dieyi C, Trivedi R, Coppola R, Maynard J, Reau N, Satram S, Chattergoon M. Prevalence of hepatitis B and D virus among a nationally representative insured population in the United States. AASLD The Liver Meeting. Boston, MA: Nov 10-14, 2023.

8. Karlitz J, Liu Y, Gupta P, Aweh G, Chung K. Burden of liver cancer among Medicaid-insured patients: A retrospective analysis of a national all-payer claims database. American College of Gastroenterology (ACG) Annual Scientific Meeting. Vancouver, CA: Oct 20-25, 2023.

9. Holman D, Drayton D, Pandit M, Diaz A, Maughn K, Dieyi C, Achter E, Peeples H. Effects of insurance coverage and antiseizure medication formulary policies on the experiences of patients with epilepsy and healthcare professionals: A qualitative study. Academy of Managed Care Pharmacy (AMCP) Nexus 2023. Orlando, FL: Oct 16-19, 2023.

10. Chung KC, Karlitz J, Liu Y, Gupta P, Aweh G. Cancer incidence among the Medicaid population: A retrospective analysis of a national all-payer claims database. Academy of Managed Care Pharmacy (AMCP) Nexus 2023. Orlando, FL: Oct 16-19, 2023.

Aug 10, 2023: Some of our Board Members are heading to ICPE, and 15 years = 15% discount!

-    Meet three of our Board members attending ICPE in Halifax;
-    It’s our 15th birthday, and you get 15% off your first subscription;
-    We are more than just a database resource – we provide database landscaping services;
-    Complete a 2-minute survey and tell us how we can better assist you!
Read more in our latest newsletter

Aug 1, 2023: We have a new vaccine profile

The Norwegian Immunisation Registry SYSVAK (national vaccination register) is a nationwide electronic vaccination register established in 1995. Until October 2009, the reporting obligation to SYSVAK only covered vaccines given in the childhood vaccination programme. During the flu pandemic in 2009, reporting was also introduced for the vaccine against pandemic flu. Starting January 2011, the reporting obligation was extended to apply to all vaccinations for all age groups in the population.

Norwegian Immunisation Registry (SYSVAK) (Norway) **

Database Contact Data

All enquiries regarding the disclosure of health data should be directed to the e-mail address: datatilgang@fhi.no

Alternate Contact

You may call the registry at (+47) 21 07 70 00, or send an e-mail to folkehelseinstituttet@fhi.no
 

References of Studies Using/Describing Database

1. Meijerink H, Shelil M, Jani-Bølstad J, Dvergsdal ET, Madslien EH, Wilberg M, Gundersen RB, Sæbø JI, Thorseng AA, Iversen BG. Does integration with national registers improve the data completeness of local COVID-19 contact tracing tools? A register-based study in Norway, May 2020 - September 2021. BMC Health Serv Res. 2024 Jan 17;24(1):96.

2. Hansen BT, Klungsøyr O, Labberton AS, Sääksvuori L, Rydland KM, Ødeskaug LE, Wisløff T, Meijerink H. Effectiveness of Text Messaging Nudging to Increase Coverage of Influenza Vaccination Among Older Adults in Norway (InfluSMS Study): Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2025 Feb 25;14:e63938.

3. Buer S, Hagen BI, Søraas A, White RA, Bø R, Ellingjord-Dale M, Istre MS, Brunvoll SH, Lerdal A, Landrø NI, Nygaard AB, Stubberud J. Executive deficits after SARS-CoV-2 infection: A cross-sectional population study. Brain Behav Immun Health. 2024 Sep 10;41:100857.

4. Rykkelid M, Wennberg HM, Richardsen E, Sørbye SW. Post-Conization HPV Vaccination and Its Impact on Viral Status: A Retrospective Cohort Study in Troms and Finnmark, 2022. Pathogens. 2024 May 2;13(5):381.

5. Dong L, Nygård M, Støer NC, Klungsøyr O, Hansen BT. Real‐world effectiveness of HPV vaccination against cervical neoplasia among birth cohorts ineligible for routine vaccination. International Journal of Cancer. 2023 Jul 15;153(2):399-406.

6. Nilsen TS, Gulseth HL, Daae A, Indseth T. Coronavirus immunisation abroad among foreign-born persons in Norway. Tidsskr Nor Laegeforen. 2022 Jun 27;142(10). English, Norwegian.

7. Hagerup-Jenssen M, Kongsrud S, Riise ØR. Suboptimal MMR2 vaccine coverage in six counties in Norway detected through the national immunisation registry, April 2014 to April 2017. Euro Surveill. 2017 Apr 27;22(17):30518.

8. Riise ØR, Laake I, Bergsaker MA, Nøkleby H, Haugen IL, Storsæter J. Monitoring of timely and delayed vaccinations: a nation-wide registry-based study of Norwegian children aged < 2 years. BMC Pediatr. 2015 Nov 13;15:180.

9. Riise O. 1066: Delay in the Norwegian Immunisation Programme. Open Forum Infect Dis. 2014 Dec;1(Suppl 1):S312–3.

10. Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013 Dec 16;31(52):6232-8.

TURKBIO (Turkey) **

Database Contact Data

Fatoş Önen
Division of Rheumatology
Dokuz Eylül University School of Medicine
İzmir
TURKEY
Email: Fatos.onen@gmail.com

Alternate Contact

TÜRK ROMATOLOJİ VERİTABANI "TÜRKBİO"
Dokuz Eylül Üniversitesi Tıp Fakültesi Hastanesi
İç Hastalıkları Ana Bilim Dalı
Romatoloji Bilim Dalı
Balçova
İzmir
TURKEY
Phone: +90 2324123721 
Email: turkbio@zitelab.eu

References of Studies Using/Describing Database

1. Uslu S, Gülle S, Sen G, Capar S, Senel S, Dalkılıc E, Akar S, Koca SS, Tufan A, Yazici A, Yilmaz S, Inanc N, Birlik M, Solmaz D, Cefle A, Goker B, Direskeneli H, Yolbas S, Steen Krogh N, Yilmaz N, Erten S, Bes C, Soysal Gündüz O, Oztürk MA, Haznedaroglu S, Yavuz S, Onen F, Sari I. Efficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis. J Clin Med. 2024 Nov 29;13(23):7266.

2. Ørnbjerg LM, Brahe CH, Linde L, Jacobsson L, Nissen MJ, Kristianslund EK, Santos MJ, Nordström D, Rotar Z, Gudbjornsson B, Onen F, Codreanu C, Lindström U, Möller B, Kvien TK, Barcelos A, Eklund KK, Tomšič M, Love TJ, Can G, Ionescu R, Loft AG, Mann H, Pavelka K, van de Sande M, van der Horst-Bruinsma IE, Suarez MP, Sánchez-Piedra C, Macfarlane GJ, Iannone F, Michelsen B, Hyldstrup LH, Krogh NS, Østergaard M, Hetland ML. Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatment. Joint Bone Spine. 2024 Jul;91(4):105729.

3. Uslu S, Gulle S, Sen G, Cefle A, Yilmaz S, Kocaer SB, Yuce Inel T, Koca SS, Yolbas S, Ozturk MA, Senel S, Inanc N, Dalkilic HE, Soysal Gunduz O, Tufan A, Akar S, Birlik AM, Sari I, Akkoc N, Onen F. Assessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry study. Sci Rep. 2024 Jun 20;14(1):14194.

4. Karakaş A, Gulle S, Can G, Dalkılıc E, Akar S, Koca SS, Pehlivan Y, Senel S, Tufan A, Ozturk MA, Yilmaz S, Yazici A, Cefle A, Yüce İnel T, Erez Y, Sari I, Birlik M, Direskeneli H, Akkoc N, Onen F. Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry. Mod Rheumatol. 2024 Mar 28;34(3):584-591.

5. Uslu S, Gülle S, Urak Ö, Şen G, Dalkılıç E, Şenel S, Akar S, İnanç N, Cefle A, Köken Avşar A, Yolbaş S, Yılmaz S, Soysal Gündüz Ö, Sarı İ, Birlik M, Akkoç N, Önen F. Biological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data results. Arch Rheumatol. 2024 Mar 20;39(2):232-241.

6. Inanc N, Abacar KY, Ozturk MA, Tufan A, Karadeniz H, Sari I, Can G, Erez Y, Pehlivan Y, Dalkilic HE, Ocak T, Cefle A, Yazici A, Senel AS, Akar S, Durak-Ediboğlu E, Koca SS, Piskin-Sagir R, Yilmaz S, Gulcemal S, Soysal-Gunduz O, Basibuyuk CS, Alkan S, Cesur TY, Onen F. Unintentional Monotherapy in Rheumatoid Arthritis Patients Receiving Tofacitinib and Drug Survival Rate of Tofacitinib. J Clin Rheumatol. 2023 Dec 1;29(8):365-369.

7. Tuğsal HY, Artin GK, Can G, Çapar S, Zengin B, Akar S, Dalkiliç HE, Şenel AS, Koca SS, Göker B, Yazici A, İnanç GN, Ellidokuz H, Akkoç N, Önen F. The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis. Turk J Med Sci. 2023 Aug;53(4):970-978.

8. Karataş A, Pişkin Sağir R, Koca SS, Dalkiliç E, Can G, Pehlivan Y, Yazici A, Inanç N, Cefle A, Ertürk Z, Akar S, Şenel S, Birlik M, Akkoç N, Önen F. Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry. Turk J Med Sci. 2023 Jun 21;53(5):1321-1329.

9. Yazici A, Özdemir Işık Ö, Dalkılıç E, Koca SS, Pehlivan Y, Şenel S, Inanc N, Akar S, Yılmaz S, Soysal Gündüz Ö, Cefle A, Karakaş ÖF, Onen F. A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry. Sci Rep. 2022 Dec 20;12(1):21972.

10. Önen F, Can G, Çapar S, Dalkılıç E, Pehlivan Y, Şenel S, Akar S, Koca SS, Tufan A, Yazıcı A, Yılmaz S, İnanç N, Sarı İ, Birlik M, Solmaz D, Cefle A, Öztürk MA, Yolbaş S, Krogh NS, Yılmaz N, Erten Ş, Bes C, Gündüz ÖS, Göker B, Haznedaroğlu S, Yavuz Ş, Yildirim Çetin G, Yıldız F, Direskeneli H, Akkoç N. A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry. Eur J Rheumatol. 2022 Apr;9(2):82-87.

Subscribe to